Communication

BAT26 Only Microsatellite Instability with High Tumor Mutation Burden—A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression

So Young Kang¹, Deok Geun Kim²,³ and Kyoung-Mee Kim¹,4, *

¹ Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
² Department of Clinical Genomic Center, Samsung Medical Center, Seoul 06351, Korea
³ Department of Digital Health, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Korea
⁴ Center of Companion Diagnostics, Samsung Medical Center, Seoul 06351, Korea
* Correspondence: kkmkys@skku.edu; Tel.: +82-2-3410-2807; Fax: +82-2-3410-6396

Abstract: Detecting microsatellite instability (MSI) in advanced cancers is crucial for clinical decision-making, as it helps in identifying patients with differential treatment responses and prognoses. BAT26 is a highly sensitive MSI marker that defines the mismatch repair (MMR) status with high sensitivity and specificity. However, isolated BAT26-only instability is rare and has not been previously reported. Of the 6476 cases tested using pentaplex MSI polymerase chain reaction, we identified two BAT26-only instability cases (0.03%) in this study. The case #1 patient was diagnosed with endometrial adenocarcinoma without MMR germline mutations. The endometrial tumor showed BAT26-only instability, partial loss of MLH1/PMS2 protein expression, and a high programmed cell death ligand 1 (PD-L1) combined positive score (CPS = 8). The tumor exhibited a somatic phosphatase and tensin homolog (PTEN) R303P missense mutation and loss of the PTEN protein. On a comprehensive cancer panel sequencing with ≥ 500 genes, the tumor showed an MSI score of 11.38% and high tumor mutation burden (TMB) (19.5 mt/mb). The case #2 patient was diagnosed with colorectal carcinoma with proficient MMR and PTEN protein loss without PTEN alteration, as well as a high PD-L1 CPS (CPS = 10). A pathogenic KRAS A146T mutation was detected with an MSI score of 3.36% and high TMB (13 mt/mb). In conclusion, BAT26-only instability is very rare and associated with PTEN protein loss, high TMB, and a high PD-L1 score. Our results suggest that patients with BAT26-only instability may show good responses to immunotherapy.

Keywords: microsatellite instability; BAT26; tumor mutation burden; PTEN; PD-L1; next-generation sequencing

1. Introduction

Microsatellite instability-high (MSI-H) is a well-recognized phenomenon resulting from defective mismatch repair (dMMR) [1]. Low-level MSI (MSI-L) varies among different cancer types and has not been clearly defined in any group [2]. For MSI testing, marker selection, marker performance, and the percentage of markers showing instability in distinguishing microsatellite stable (MSS)/MSI-L from MSI-H are important issues when determining the MSI test results [3].

The mononucleotide marker BAT26 (a poly(A) tract localized in the fifth intron of the mutS homolog (MSH)-2) [4] is an extremely sensitive and specific quasi-monomorphic marker for testing MSI. The use of mononucleotide markers alone has led to the correct identification of 97% of MSI-H cases, and BAT26 is specific and sensitive in identifying MSI-H cases [5,6]. Cicek et al. reported that 91% of MSI-H cases demonstrated instability at the BAT26 locus, and the BAT26-only MSI test showed 94% sensitivity and 98% specificity.
for the identification of tumors with MMR deficiency, suggesting BAT26 as the best single marker to identify tumors with MSI-H [7]. In our institute, the MSI polymerase chain reaction (PCR) test was performed for 6476 cases, and BAT26-only instability was identified in two cases (0.03%), which is very rare, and there have been no previous reports of such cases in the literature.

Herein, we report two rare BAT26-only instability cases associated with high tumor mutation burden (TMB), phosphatase and tensin homolog (PTEN) protein loss, and high PD-L1 expression via a comprehensive cancer panel test and immunohistochemistry.

2. Results

2.1. Case Report #01

A 61-year-old woman visited the hospital for an operation of asymptomatic grade 2 endometrial endometrioid carcinoma incidentally diagnosed during regular health checks. A total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node dissection were performed. The tumor invaded less than one half of the myometrium with no metastasis in any of the 10 regional lymph nodes (pT1aN0M0). The endometrial tumor showed BAT26-only instability with a partial loss of MLH1/PMS2 expression and a high PD-L1 combined positive score (CPS = 8). The tumor showed an “immune-excluded” microenvironment (immune cells aggregating at the tumor boundaries). NGS revealed the PTEN R303P alteration, while IHC demonstrated the PTEN protein loss (Figure 1). Cooccurring genetic alterations included KRAS (G12A) and AT-rich interaction domain 1A (p.Q1519Pfs*13 and p.D1850Tfs*33) mutations (Supplementary Table S1). The tumor showed an MSI score of 11.38%, along with a high TMB (19.5 mt/mb). In NGS, the microsatellite (MS) loci, including EWS RNA-binding protein 1, paired box 8, and MYB, also showed instability in endometrial tumors (Supplementary Table S2). The patient had two first-degree relatives with endometrial and breast cancers, respectively. The patient was previously diagnosed with colorectal cancer eight years ago, and the colon tumor was MSS and proficient MMR (pMMR). The clinician provided genetic counseling based on the patient’s cancer diagnosis and family history. After obtaining consent, a genetic analysis of the patient’s peripheral blood was performed via whole-genome sequencing, and no MMR germline mutation was found; thus, the patient was diagnosed with Lynch-like syndrome.

Figure 1. (A) In BAT26-only instability cancer, a mononucleotide (A) repeat was deleted by erroneous replication from the 3′ region of MSH2 exon 5 on chromosome 2. Amplification profile from case #01 using pentaplex PCR showing a BAT26-only unstable phenotype in tumor tissue. (B) Immunohistochemistry of tumor section from case #01 using antibodies targeting MLH1 and MSH2, showing the expression of mismatch repair proteins in tumor cells (partial mismatch repair deficiency), PD-L1 expression in lymphocytes (immune-excluded tumor microenvironment; CPS = 8), and PTEN protein loss in tumor sections. All images are at 2.0× magnification.

2.2. Case Report #02

A 48-year-old woman visited the emergency department due to hematochezia. An urgent colonoscopy detected a mass in the sigmoid colon, and a biopsy confirmed an adenocarcinoma. Of the 5903 colorectal cancer cases tested with MSI PCR, this case was the only one (0.017%) with BAT26-only instability. After the cancer diagnosis, a low anterior resection was performed. A histopathological examination of the surgically resected sample revealed moderately differentiated adenocarcinoma. Pathological staging identified the cancer as stage IIIA with invasion into the muscularis propria (pT2) and regional lymph node metastasis to 3–21 regional lymph nodes (pN1b). The tumor was pMMR with a high PD-L1 CPS score (CPS = 10) and an immune-excluded tumor microenvironment. The tumor showed a loss of the PTEN protein without a PTEN alteration (Figure 2).
Figure 1. (A) In BAT26-only instability cancer, a mononucleotide (A) repeat was deleted by erroneous replication from the 3′ region of MSH2 exon 5 on chromosome 2. Amplification profile from case #01 using pentaplex PCR showing a BAT26-only unstable phenotype in tumor tissue. (B) Immunohistochemistry of tumor section from case #01 using antibodies targeting MLH1 and MSH2, showing the expression of mismatch repair proteins in tumor cells (partial mismatch repair deficiency), PD-L1 expression in lymphocytes (immune-excluded tumor microenvironment; CPS = 8), and PTEN protein loss in tumor sections. All images are at 2.0× magnification.

2.2. Case Report #02

A 48-year-old woman visited the emergency department due to hematochezia. An urgent colonoscopy detected a mass in the sigmoid colon, and a biopsy confirmed an adenocarcinoma. Of the 5903 colorectal cancer cases tested with MSI PCR, this case was the only one (0.017%) with BAT26-only instability. After the cancer diagnosis, a low anterior resection was performed. A histopathological examination of the surgically resected sample revealed moderately differentiated adenocarcinoma. Pathological staging identified the cancer as stage IIIA with invasion into the muscularis propria (pT2) and regional lymph node metastasis to 3–21 regional lymph nodes (pN1b). The tumor was pMMR with a high PD-L1 CPS score (CPS = 10) and an immune-excluded tumor microenvironment. The tumor showed a loss of the PTEN protein without a PTEN alteration (Figure 2).

The cooccurring genetic alterations were pathogenic KRAS A146T mutations. The MSI score was 3.36%, and the tumor showed high TMB (13 mt/mb). The EPCAM R153T variant from ClinVar was annotated as nonpathogenic but showed an intact EPCAM protein expression. Two variants (Q419K and Q629R) were classified as benign or likely benign within MSH2. Two variants (P18L and G25D) of uncertain clinical significance (VUS) were observed in mutY DNA glycosylase. The mononucleotide MS markers at MYB and lysosomal associated membrane protein 1 loci were unstable (Supplementary Table S2).
whereas, in melanoma, squamous cell carcinoma, and lung carcinoma, high TMB is fairly common, but MSI-H is very uncommon. These data suggest that the MSI-H pathway appears to be a common phenomenon in gastrointestinal and gynecologic carcinogenesis but is less frequently involved in other cancer types [14].

In the present study, we found BAT26-only instability in colorectal and endometrial carcinomas where MSI-H is commonly observed. One patient with PTEN inactivation showed PTEN mutation. Although this was a retrospective study and the number of
patients with BAT26-only instability was low owing to its rarity, we demonstrated PTEN protein loss, high TMB, and high PD-L1 expression in these rare cases. We previously reported that PTEN mutations are frequently observed in MSI-H/dMMR tumors [15]. The scope of PTEN functions has recently expanded with new potential implications for immunotherapy-based approaches [16]. PTEN protein loss and high TMB are frequently observed in immune-excluded tumor microenvironments [17], and our findings are consistent with those of prior studies [18]. The present study also supports the view that BAT26-only instability arises largely due to the basal instability level of cancer genomes rather than representing a distinct disease category, such as MSI-L tumors [19]. Out of 6476 cases tested for pentaplex MSI-PCR, we identified two BAT26-only instability cancers. Unexpectedly, those two cases were associated with high TMB and high PD-L1 expression. Given that high TMB and PD-L1 overexpression are predictive biomarkers for immunotherapy [20], we suggest that, although very rare, patients with BAT26-only instability cancer need further tests for TMB and PD-L1 and would be a good candidate for immunotherapy.

As an intermediate between MSI-H and MSS cases, MSI-L tumors are thought to comprise 2–10% of colorectal cancers [21]. However, whether these genomes represent a unique disease entity that can be clearly separated from the MSI-H and MSS genomes with distinct clinical or genetic features has to be further elucidated [22]. Kim et al. reported that MSI-L arises due to the basal instability level of cancer genomes rather than representing a distinct disease category [19,23], and MSI-L cases may represent the pre-MSI-H phase during cancer progression. Although previous studies have demonstrated MSI-L tumors with the use of an extended set of MS markers (Supplementary Table S3), BAT26-only instability, which should be classified as MSI-L by its definition, showed somewhat different characteristics compared to MSI-L tumors. Gianninni et al. reported that MSI events near splicing sites may alter the transcript level or splicing pattern of target genes, as shown for MRE11 [24]. Zhou et al. previously reported that the quasi-monomorphic allelic nature of BAT26 in the normal population has the potential functional significance of MS repeats around splice sites [25]. Our two BAT26-only MSI-L mutants showed poly-T/A repeats of the MYB MS marker, which is frequently unstable in MLH1 and MSH2 mutation carriers [26,27]. The current cases showed no MMR germline mutations.

In summary, we described two rare cases of BAT26-only instability associated with high TMB, PTEN protein loss, and high PD-L1 CPS, suggesting that patients with BAT26-only instability are good candidates for immunotherapy.

4. Materials and Methods

4.1. Patient Acquisition

Of the 6476 cases between December, 2017 and February, 2020, we identified two cases with BAT26-only instability based on the pentaplex MSI PCR results in the Department of Pathology of the Samsung Medical Center. This study was performed in accordance with the Institutional Review Board guidelines (IRB 2020-06-045-001) for the data analysis and review of the medical records.

4.2. MSI Test

The tumor-rich areas were circled by pathologists on hematoxylin and eosin-stained 4-µm-thick slides of formalin-fixed, paraffin-embedded tissues for dissection. The MSI status was determined via multiplex PCR, which amplified five quasi-monomorphic mononucleotide repeat markers (pentaplex: BAT25, BAT26, NR21, NR24, and NR27), as previously described [28,29].

4.3. Immunohistochemistry (IHC)

IHC staining was performed on paraffin-embedded 3-µm-thick tissue sections for MSH2, mutL homolog 1 (MLH1), MSH6, PMS1 homolog 2 (PMS2), epithelial cell adhesion molecule (EPCAM), programmed cell death ligand 1 (PD-L1), and PTEN [15,30]. An IHC analysis was performed using a Ventana Bench Mark XT autoimmunostainer (Ventana
Medical Systems, Tucson, AZ, USA) after incubation with the primary antibodies at 37 °C for 30 min, followed by standard Ventana signal amplification and counterstaining with hematoxylin for 4 min, as previously described [15,30].

4.4. Next-Generation Sequencing (NGS) with Comprehensive Cancer Panel

Library preparation was performed using the hybrid capture-based Illumina TruSight Oncology 500 (TSO500; Illumina, San Diego, CA, USA), as previously described [30]. Data outputs exported from the TSO 500 pipeline (Illumina) were annotated using the Ensembl Variant Effect Predictor Annotation Engine [31] with information from several databases and alignment to the hg19 human reference genome (http://genome.ucsc.edu/) (accessed on 1 March 2022). Mutation allele frequencies below the predefined thresholds were considered to be wildtypes.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms231810730/s1. References [32–49] are cited in the supplementary materials

Author Contributions: S.Y.K. and K.-M.K. designed and supervised the study. S.Y.K. and K.-M.K. collected the tissue samples and clinical data and performed the histopathological examinations. S.Y.K., D.G.K. and K.-M.K. analyzed the data. S.Y.K., D.G.K. and K.-M.K. conducted the experiments. S.Y.K. and K.-M.K. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Basic Science Research Program via the National Research Foundation of Korea (NRF), funded by the Ministry of Science and Information and Communication Technology (ICT) (NRF-2017R1A2B4012436), and by a grant from the Korea Health Technology R&D Project via the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant numbers: HR20C0025 and HI21C1137).

Institutional Review Board Statement: This study was performed in accordance with the Institutional Review Board guidelines of the Samsung Medical Center (IRB 2020-06-045-001) for data analysis and investigational treatments. All procedures performed in the study involving human participants were in accordance with the ethical standards of the Trust and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent Statement: All patients provided informed consent to participate in this study.

Data Availability Statement: The data are available upon reasonable request. The data that support the findings of this study are available upon request from the corresponding author, K.-M.K.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Boland, C.R.; Thibodeau, S.N.; Hamilton, S.R.; Sidransky, D.; Eshleman, J.R.; Burt, R.W.; Meltzer, S.J.; Rodriguez-Bigas, M.A.; Fodde, R.; Ranzani, G.N.; et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998, 58, 5248–5257. [PubMed]
2. Tomlinson, I.; Halford, S.; Aaltonen, L.; Hawkins, N.; Ward, R. Does MSI-low exist? J. Pathol. 2002, 197, 6–13. [CrossRef] [PubMed]
3. Hatch, S.B.; Lightfoot, H.M., Jr; Garvacki, C.P.; Moore, D.T.; Calvo, B.F.; Woosley, J.T.; Sciarrotta, J; Funkhouser, W.K.; Farber, R.A. Microsatellite instability testing in colorectal carcinoma: Choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin. Cancer Res. 2005, 11, 2180–2187. [CrossRef] [PubMed]
4. Liu, B.; Parsons, R.E.; Hamilton, S.R.; Petersen, G.M.; Lynch, H.T.; Watson, P.; Markowitz, S.; Willson, J.K.; Green, J.; de la Chapelle, A.; et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res. 1994, 54, 4590–4594.
5. Dietmaier, W.; Wallinger, S.; Bocker, T.; Kullmann, F.; Fishel, R.; Ruschoff, J. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression. Cancer Res. 1997, 57, 4749–4756.
6. Hoang, J.M.; Cottu, P.H.; Thuille, B.; Salmon, R.J.; Thomas, G.; Hamelin, R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 1997, 57, 300–303.
7. Cieck, M.S.; Lindor, N.M.; Gallinger, S.; Bapat, B.; Hopper, J.L.; Jenkins, M.A.; Young, J.; Buchanan, D.; Walsh, M.D.; Le Marchand, L.; et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J. Mol. Diagn 2011, 13, 271–281. [CrossRef]
8. Compton, C.C.; Fielding, L.P.; Burgart, L.J.; Conley, B.; Cooper, H.S.; Hamilton, S.R.; Hammond, M.E.H.; Henson, D.E.; Hutter, R.V.; Nagle, R.B. Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999. Arch. Pathol. Lab. Med. 2000, 124, 979–994. [CrossRef]
9. Nguyen, L.H.; Goel, A.; Chung, D.C. Pathways of Colorectal Carcinogenesis. Gastroenterology 2020, 158, 291–302. [CrossRef]
10. Umar, A.; Boland, C.R.; Terdiman, J.P.; Syngal, S.; de la Chapelle, A.; Rüschoff, J.; Fishel, R.; Lindor, N.M.; Burgart, L.J.; Hamelin, R.; et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004, 96, 261–268. [CrossRef]
11. Brennemot, C.; Buhard, O.; Jourdan, F.; Flejou, J.F.; Duval, A.; Hamelin, R. Mononucleotide repeats BAT26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: Implications for population screening. Int. J. Cancer 2005, 113, 446–450. [CrossRef] [PubMed]
12. Pastrello, C.; Baglioni, S.; Tibiletti, M.G.; Papi, L.; Fornasarig, M.; Morabito, A.; Agostini, M.; Genuardi, M.; Viel, A. Stability of BAT26 in tumours of hereditary nonpolyposis colorectal cancer patients with MSH2 intragenic deletion. Eur. J. Hum. Genet. 2006, 14, 63–68. [CrossRef] [PubMed]
13. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.; et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017, 9, 34. [CrossRef] [PubMed]
14. Chang, L.; Chang, M.; Chang, H.M.; Chang, F. Microsatellite instability: A predictive biomarker for cancer immunotherapy. Appl. Immunohistochem. Mol. Morphol. 2018, 26, e15–e21. [CrossRef]
15. Kim, B.; Kang, S.Y.; Kim, D.; Heo, Y.J.; Kim, K.M. PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression. Cancers 2020, 12, 1724. [CrossRef]
16. Piro, G.; Carbone, C.; Carbognin, L.; Pilotto, S.; Ciccarese, C.; Iacovelli, R.; Milella, M.; Bria, E.; Tortora, G. Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers 2019, 11, 1525. [CrossRef]
17. Kim, H.; Heo, Y.J.; Cho, Y.A.; Kang, S.Y.; Ahn, S.; Kim, K. Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. Clin. Transl. Oncol. 2022, 24, 556–567. [CrossRef] [PubMed]
18. Catalano, I.; Grassi, E.; Bertotti, A.; Trusolino, L. Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. Trends Cancer 2019, 5, 779–788. [CrossRef]
19. Halford, S.; Sasiendi, P.; Rowan, A.; Wasan, H.; Bodmer, W.; Talbot, I.; Hawkins, N.; Ward, R.; Tomlinson, I. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res. 2002, 62, 53–57. [CrossRef]
20. Bai, R.; Lv, Z.; Xu, D.; Cui, J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020, 8, 34. [CrossRef] [PubMed]
21. Thibodeau, S.N.; French, A.J.; Cunningham, J.M.; Tester, D.; Burgart, L.J.; Roche, P.C.; McDonnell, S.K.; Schaid, D.J.; Vockley, C.W.; Michels, V.V.; et al. Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998, 58, 1713–1718. [PubMed]
22. Kim, T.M.; Laird, P.W.; Park, P.J. The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes. Cell 2013, 153, 858–868. [CrossRef] [PubMed]
23. Kim, T.M.; Park, P.J. A genome-wide view of microsatellite instability: Old stories of cancer mutations revisited with new sequencing technologies. Cancer Res. 2014, 74, 6377–6382. [CrossRef]
24. Giannini, G.; Rinaldi, C.; Ristori, E.; Ambrosini, M.I.; Cerignoli, F.; Viel, A.; Bidoli, E.; Berni, S.; D’Amati, G.; Scambia, G. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 2004, 23, 2640–2647. [CrossRef] [PubMed]
25. Zhou, X.-P.; Hoang, J.-M.; Cottu, P.; Thomas, G.; Hamelin, R. Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors. Oncogene 1997, 15, 1713–1718. [CrossRef]
26. Thompson, M.A.; Flegg, R.; Westin, E.H.; Ramsay, R.G. Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oncogene 1997, 14, 1715–1723. [CrossRef]
27. Mead, L.J.; Jenkins, M.A.; Young, J.; Royce, S.G.; Smith, L.; St John, D.J.; Macrae, F.; Giles, G.G.; Hopper, J.L.; Southey, M.C. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes. Clin. Cancer Res. 2007, 13, 2865–2869. [CrossRef]
28. Kang, S.Y.; Park, C.K.; Chang, D.K.; Kim, J.W.; Son, H.J.; Cho, Y.B.; Yun, S.H.; Kim, H.C.; Kwon, M.; Kim, K.M. Lynch-like syndrome: Characterization and comparison with EPCAC deletion carriers. Int. J. Cancer 2015, 136, 1568–1578. [CrossRef]
29. Kang, S.Y.; Kim, K.M. Highly sensitive duplex MSI test and BAT40 germline polymorphism. Apmis 2021, 129, 607–615. [CrossRef]
30. Kang, S.Y.; Kim, D.G.; Ahn, S.; Ha, S.Y.; Jang, K.T.; Kim, K.M. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers. Pathol. Res. Pract. 2022, 233, 153874. [CrossRef]
31. Pestinger, V.; Smith, M.; Sillo, T.; Findlay, J.M.; Laes, J.F.; Martin, G.; Middleton, G.; Taniere, P.; Beggs, A.D. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Mol. Diagn 2020, 24, 339–349. [CrossRef] [PubMed]
32. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513, 202. [CrossRef]
33. Levine, D.A. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497, 67–73. [CrossRef] [PubMed]
34. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012, 487, 330. [CrossRef] [PubMed]

35. de la Chapelle, A.; Hampel, H. Clinical relevance of microsatellite instability in colorectal cancer. *J Clin Oncol* 2010, 28, 3380–3387. [CrossRef]

36. Kim, J.H.; Shin, S.H.; Kwon, H.J.; Cho, N.Y.; Kang, G.H. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. *Virochon Archiv.* 2009, 455, 485–494. [CrossRef]

37. Hampel, H.; Frankel, W.L.; Martin, E.; Khanduja, K.; Kuebler, P.; Clendenning, M.; Sotamaa, K.; Prior, T.; Westman, J.A.; et al. Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer. *J. Clin. Oncol.* 2008, 26, 5783–5788. [CrossRef]

38. Hampel, H.; Frankel, W.L.; Martin, E.; Arnold, M.; Khanduja, K.; Kuebler, P.; Nakagawa, H.; Sotamaa, K.; Prior, T.W.; Westman, J.; et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N. Engl. J. Med.* 2005, 352, 1851–1860. [CrossRef]

39. Kohonen-Corish, M.R.J.; Daniel, J.J.; Chan, C.; Lin, B.P.C.; Kwun, S.Y.; Dent, O.F.; Dhillon, V.S.; Trent, R.J.A.; Chapuis, P.H.; Bokey, E.L. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. *J. Clin. Oncol.* 2005, 23, 2318–2324. [CrossRef]

40. Wright, C.M.; Dent, O.F.; Newland, R.C.; Barker, M.; Chapuis, P.H.; Bokey, E.L.; Young, J.P.; Leggett, B.A.; Jass, J.R.; Macdonald, G.A. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. *Gut* 2005, 54, 103–108. [CrossRef]

41. Pawlik, T.M.; Raut, C.P.; Rodriguez-Bigas, M.A. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers* 2004, 20, 199–206. [CrossRef] [PubMed]

42. Halford, S.E.; Sawyer, E.J.; Lambros, M.B.; Gorman, P.; Macdonald, N.D.; Talbot, I.C.; Foulkes, W.D.; Gillett, C.E.; Barnes, D.M.; Akslen, L.A.; et al. MSI-low, a real phenomenon which varies in frequency among cancer types. *J. Pathol.* 2003, 201, 389–394. [CrossRef] [PubMed]

43. Laiho, P.; Launonen, V.; Lahermo, P.; Esteller, M.; Guo, M.; Herman, J.G.; Mecklin, J.P.; Järvinen, H.; Sistonen, P.; Kim, K.M.; et al. Low-level microsatellite instability in most colorectal carcinomas. *Cancer Res.* 2002, 62, 1166–1170. [PubMed]

44. Whitehall, V.L.; Walsh, M.D.; Young, J.; Leggett, B.A.; Jass, J.R. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. *Cancer Res.* 2001, 61, 827–830. [CrossRef]

45. Alexander, J.; Watanabe, T.; Wu, T.T.; Rashid, A.; Li, S.; Hamilton, S.R. Histopathological identification of colon cancer with microsatellite instability. *Am. J. Pathol.* 2001, 158, 527–535. [CrossRef]

46. Gonzalez-Garcia, I.; Moreno, V.; Navarro, M.; Marti-Rague, J.; Marcuello, E.; Benasco, C.; Campos, O.; Capella, G.; Peinado, M.A. Standardized approach for microsatellite instability detection in colorectal carcinomas. *J. Natl. Cancer Inst.* 2000, 92, 544–549. [CrossRef]

47. Gryfe, R.; Gallinger, S. Microsatellite instability, mismatch repair deficiency, and colorectal cancer. *Surgery* 2001, 130, 17–20. [CrossRef]

48. Jass, J.R.; Biden, K.G.; Cummings, M.C.; Simms, L.A.; Walsh, M.; Schoch, E.; Meltzer, S.J.; Wright, C.; Searle, J.; Young, J.; et al. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. *J. Clin. Pathol.* 1999, 52, 455–460. [CrossRef]

49. Mirabelli-Primdahl, L.; Gryfe, R.; Kim, H.; Millar, A.; Luceri, C.; Dale, D.; Holowaty, E.; Bapat, B.; Gallinger, S.; Redston, M. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res.* 1999, 59, 3346–3351.